Table 2 Recurrent ischemic stroke and secondary safety outcomes of patients with and without use of pioglitazone
Outcome | Pioglitazone (n = 3189) | Non-pioglitazone (n = 6378) | Pioglitazone vs. non-pioglitazone | |
|---|---|---|---|---|
SHR (95% CI) | p-value | |||
Primary analysis: propensity score matching | ||||
Recurrent ischemic stroke, n (%) | 598 (18.8) | 1273 (20.0) | 0.91 (0.84, 0.99) | 0.033 |
Sensitivity analysis: IPTW | ||||
Recurrent ischemic stroke, % | 19.0 | 21.2 | 0.89 (0.80, 0.99) | 0.025 |
Secondary outcomes | ||||
Acute myocardial infarction, n (%) | 119 (3.7) | 265 (4.2) | 0.79 (0.65, 0.97) | 0.021 |
Hospitalization for heart failure, n (%) | 200 (6.3) | 410 (6.4) | 0.99 (0.85, 1.15) | 0.867 |
All-cause mortality, n (%) | 560 (17.6) | 1158 (18.2) | 0.94 (0.83, 1.06) | 0.320 |
Cardiovascular death, n (%) | 362 (11.4) | 731 (11.5) | 0.95 (0.81, 1.11) | 0.523 |
Bladder cancer, n (%) | 10 (0.31) | 11 (0.17) | 1.34 (0.62, 2.88) | 0.456 |